Literature DB >> 21760551

BV6, an IAP antagonist, activates apoptosis and enhances radiosensitization of non-small cell lung carcinoma in vitro.

Wenyan Li1, Bo Li, Nicholas J Giacalone, Artour Torossian, Yunguang Sun, Kathy Niu, Opal Lin-Tsai, Bo Lu.   

Abstract

INTRODUCTION: Defects in the apoptosis pathway limit the effectiveness of radiation in non-small cell lung cancer (NSCLC) therapy. BV6 is an antagonist of cIAP1 and XIAP, members of the inhibitors of apoptosis (IAP) family. We investigated the potential of BV6 to sensitize NSCLC cell lines to radiation.
METHODS: HCC193 and H460 lung cancer cell lines were treated with BV6 to investigate the effects of drug administration on cell proliferation, apoptosis, inhibition of XIAP and cIAP1, and radiosensitivity. Subsequent immunoblotting and Hoechst staining were used to determine the role of apoptosis in radiosensitization. Finally, the pathway of apoptosis was characterized by Western blot analysis for cleaved caspase-8 and cleaved caspase-9 and enzyme-linked immunosorbent assays for TNF-α.
RESULTS: HCC193 was found to be more sensitive than H460 to BV6-induced apoptosis in a concentration-dependent and time-dependent manner. BV6 significantly sensitized both cell lines to radiation (HCC193-DER = 1.38, p < 0.05 at 1 μM BV6; H460-DER = 1.42, p < 0.05 at 5 μM BV6), but a higher concentration of and longer incubation time with BV6 was necessary for H460 cells. The BV6-induced radiosensitization of HCC193 favored the extrinsic pathway of apoptosis, whereas that of H460 favored the intrinsic pathway.
CONCLUSIONS: BV6, an IAP antagonist, significantly enhanced the radiosensitization of HCC193 and H460 cells in vitro. More research is warranted to test the mechanism of action of BV6 and to assess its potential in vivo and in the clinical setting.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21760551      PMCID: PMC3196825          DOI: 10.1097/JTO.0b013e318226b4a6

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  43 in total

1.  cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination.

Authors:  Mathieu J M Bertrand; Snezana Milutinovic; Kathleen M Dickson; Wai Chi Ho; Alain Boudreault; Jon Durkin; John W Gillard; James B Jaquith; Stephen J Morris; Philip A Barker
Journal:  Mol Cell       Date:  2008-06-20       Impact factor: 17.970

2.  Both cIAP1 and cIAP2 regulate TNFalpha-mediated NF-kappaB activation.

Authors:  D J Mahoney; H H Cheung; R Lejmi Mrad; S Plenchette; C Simard; E Enwere; V Arora; T W Mak; E C Lacasse; J Waring; R G Korneluk
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-12       Impact factor: 11.205

3.  Regulation of apoptosis by XIAP ubiquitin-ligase activity.

Authors:  Andrew J Schile; María García-Fernández; Hermann Steller
Journal:  Genes Dev       Date:  2008-08-15       Impact factor: 11.361

Review 4.  Smac mimetics and TNFalpha: a dangerous liaison?

Authors:  Hao Wu; Jurg Tschopp; Su-Chang Lin
Journal:  Cell       Date:  2007-11-16       Impact factor: 41.582

5.  Transfection of Smac/DIABLO sensitizes drug-resistant tumor cells to TRAIL or paclitaxel-induced apoptosis in vitro.

Authors:  Hong Luan Mao; Pei Shu Liu; Jing Fang Zheng; Pei Hai Zhang; Li Guang Zhou; Gang Xin; Chunxi Liu
Journal:  Pharmacol Res       Date:  2007-09-15       Impact factor: 7.658

6.  IAP antagonists target cIAP1 to induce TNFalpha-dependent apoptosis.

Authors:  James E Vince; W Wei-Lynn Wong; Nufail Khan; Rebecca Feltham; Diep Chau; Afsar U Ahmed; Christopher A Benetatos; Srinivas K Chunduru; Stephen M Condon; Mark McKinlay; Robert Brink; Martin Leverkus; Vinay Tergaonkar; Pascal Schneider; Bernard A Callus; Frank Koentgen; David L Vaux; John Silke
Journal:  Cell       Date:  2007-11-16       Impact factor: 41.582

7.  IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis.

Authors:  Eugene Varfolomeev; John W Blankenship; Sarah M Wayson; Anna V Fedorova; Nobuhiko Kayagaki; Parie Garg; Kerry Zobel; Jasmin N Dynek; Linda O Elliott; Heidi J A Wallweber; John A Flygare; Wayne J Fairbrother; Kurt Deshayes; Vishva M Dixit; Domagoj Vucic
Journal:  Cell       Date:  2007-11-16       Impact factor: 41.582

8.  TNF-alpha induces two distinct caspase-8 activation pathways.

Authors:  Lai Wang; Fenghe Du; Xiaodong Wang
Journal:  Cell       Date:  2008-05-16       Impact factor: 41.582

Review 9.  IAP-targeted therapies for cancer.

Authors:  E C LaCasse; D J Mahoney; H H Cheung; S Plenchette; S Baird; R G Korneluk
Journal:  Oncogene       Date:  2008-10-20       Impact factor: 9.867

10.  Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines.

Authors:  Tsutomu Iwasa; Isamu Okamoto; Minoru Suzuki; Takahito Nakahara; Kentaro Yamanaka; Erina Hatashita; Yuki Yamada; Masahiro Fukuoka; Koji Ono; Kazuhiko Nakagawa
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 13.801

View more
  12 in total

1.  Smac mimetic compound LCL161 sensitizes esophageal carcinoma cells to radiotherapy by inhibiting the expression of inhibitor of apoptosis protein.

Authors:  Qin Qin; Yun Zuo; Xi Yang; Jing Lu; Liangliang Zhan; Liping Xu; Chi Zhang; Hongcheng Zhu; Jia Liu; Zheming Liu; Guangzhou Tao; Shengbin Dai; Xizhi Zhang; Jianxin Ma; Jing Cai; Xinchen Sun
Journal:  Tumour Biol       Date:  2013-10-30

2.  Debio 1143, an antagonist of multiple inhibitor-of-apoptosis proteins, activates apoptosis and enhances radiosensitization of non-small cell lung cancer cells in vitro.

Authors:  Ningbo Liu; Zhen Tao; Justin M Le Blanc; Nicholas G Zaorsky; Yunguang Sun; Grégoire Vuagniaux; Adam P Dicker; Bo Lu
Journal:  Am J Cancer Res       Date:  2014-11-19       Impact factor: 6.166

3.  Ubiquitin-binding domain in ABIN1 is critical for regulating cell death and inflammation during development.

Authors:  Ming Li; Yongbo Liu; Chengxian Xu; Qun Zhao; Jianling Liu; Mingyan Xing; Xiaoming Li; Haiwei Zhang; Xiaoxia Wu; Lingxia Wang; Yangjing Ou; Xuanhui Wu; Xiaoming Zhao; Han Liu; Lin Qiu; Fang Li; Jinbao Li; Wuwei Rong; Yan Luo; Jiangshan Deng; Xiuzhe Wang; Zhichao Wang; Yuwu Zhao; Ankang Lv; Qingfeng Li; Haibing Zhang
Journal:  Cell Death Differ       Date:  2022-04-16       Impact factor: 12.067

4.  The SMAC mimetic BV6 induces cell death and sensitizes different cell lines to TNF-α and TRAIL-induced apoptosis.

Authors:  Mohamed El-Mesery; Mohamed E Shaker; Abdelaziz Elgaml
Journal:  Exp Biol Med (Maywood)       Date:  2016-07-28

5.  Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer.

Authors:  Miran Rada; Sameera Nallanthighal; Jennifer Cha; Kerry Ryan; Jessica Sage; Catherine Eldred; Maria Ullo; Sandra Orsulic; Dong-Joo Cheon
Journal:  Oncogene       Date:  2018-05-17       Impact factor: 9.867

6.  XIAP-targeting drugs re-sensitize PIK3CA-mutated colorectal cancer cells for death receptor-induced apoptosis.

Authors:  M Ehrenschwender; S Bittner; K Seibold; H Wajant
Journal:  Cell Death Dis       Date:  2014-12-11       Impact factor: 8.469

7.  Inhibitor of Apoptosis Proteins: Promising Targets for Cancer Therapy.

Authors:  Thomas W Owens; Andrew P Gilmore; Charles H Streuli; Fiona M Foster
Journal:  J Carcinog Mutagen       Date:  2013-05-27

8.  Novel smac mimetic APG-1387 elicits ovarian cancer cell killing through TNF-alpha, Ripoptosome and autophagy mediated cell death pathway.

Authors:  Bao-Xia Li; Heng-Bang Wang; Miao-Zhen Qiu; Qiu-Yun Luo; Han-Jie Yi; Xiang-Lei Yan; Wen-Tao Pan; Lu-Ping Yuan; Yu-Xin Zhang; Jian-Hua Xu; Lin Zhang; Da-Jun Yang
Journal:  J Exp Clin Cancer Res       Date:  2018-03-12

9.  Interferon-γ and Smac mimetics synergize to induce apoptosis of lung cancer cells in a TNFα-independent manner.

Authors:  Qin Hao; Hua Tang
Journal:  Cancer Cell Int       Date:  2018-06-14       Impact factor: 5.722

10.  The IAP Antagonist SM-164 Eliminates Triple-Negative Breast Cancer Metastasis to Bone and Lung in Mice.

Authors:  Wei Lei; Rong Duan; Jinbo Li; Xin Liu; Alissa Huston; Brendan F Boyce; Zhenqiang Yao
Journal:  Sci Rep       Date:  2020-04-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.